Adoptive immunotherapy with donor leukocytes has emerged as a promising strategy for the treatment of myeloma recurrence after allogeneic transplantation. 2.9 × 10 8 /kg donor mononuclear cells containing 1.4% CD34 + and 37% CD3 + cells were administered to a 48-year-old patient with non-secretory plasmablastic myeloma relapsing 9 months after a blood stem cell transplant from his HLA-identical sibling. In view of the extensive marrow infiltration and the aggressive behaviour of the disease, the donor cells were preceded by a course of EDAP chemotherapy. There was rapid clinical improvement, and CR was achieved on day 30 post infusion. However, three subcutaneous plasmacytomas showing anaplastic features developed within a few days. These failed to respond to interferon-␣ and continued to grow for 5 weeks in the absence of marrow plasmacytosis or other evidence of systemic disease. Grade 3 acute liver GVHD developed on day 79 which was controlled with immunosuppression. Overt systemic relapse occurred on day 90 as the GVHD came under control. The course of our case suggests highly proliferative malignant cells may escape the graft-versustumour effect of immunocompetent allogeneic cells in extramedullary sites subsequently resulting in overt systemic relapse if left untreated. New approaches are needed to deal with the problem of extramedullary disease recurrence. Keywords: multiple myeloma; extramedullary plasmacytoma; graft-versus-myeloma; immunotherapy; graft-versushost disease Even though high-dose chemotherapy and autologous transplantation induce prolonged remissions in a significant proportion of patients with myeloma and prolong survival, plant-related deaths and disease recurrence.
plant-related deaths and disease recurrence. 2 While the optimal conditioning regimen is yet to be established, salvage strategies employed aim primarily at palliation or at a temporary disease control.
Cell or cytokine-mediated immunotherapy with leukocytes from the original donor, interferon-␣ or interleukin-2 can induce remission in a variety of hematologic malignancies relapsing or persisting after allogeneic transplantation, including multiple myeloma. [3] [4] [5] [6] [7] Early experience effected some optimism in the problematic management of post-allograft relapse [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] despite the fact that immunotherapy itself is associated with significant morbidity and mortality as well as disease recurrence when GVHD is controlled. 8 We describe the unusual clinical course of a patient who received donor leukocytes for rapidly progressive myeloma after an allogeneic blood stem cell transplant, and then developed multiple subcutaneous plasmacytomas while remaining in marrow remission.
Case report
A 47-year-old man presented in January 1994 with stage IIA non-secretory plasmablastic myeloma. At diagnosis his renal function and skeletal survey were normal while the C-reactive protein was 7.6 g/dl. The Hb was 9.6 g/dl and the BM biopsy showed 60% immature plasma cells. He was initially treated with four cycles of VAD (vincristineadriamycin-dexamethasone) without response. He then received eight cycles of VBMCP (vincristine-BCNU-melphalan-cyclophosphamide-prednisolone) which resulted in modest improvement. Due to his young age and suboptimal response to chemotherapy he underwent a peripheral blood stem cell allograft from his HLA-identical brother after conditioning with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg). GVHD prophylaxis comprised of cyclosporine and methotrexate. Engraftment was prompt, and mucocutaneous grade I acute GVHD developed which resolved spontaneously. Complete remission was attained after the transplant. Cyclosporine was tapered from day +60, but was maintained at 100 mg/day because of limited chronic GVHD of the skin. Marrow examination 8 months after the allograft showed no evidence of myeloma.
Nine months after the allograft and while still on cyclo-sporine he was admitted with a 2-week history of anorexia, weight loss and general weakness. The Hb was 8.4 g/dl, platelets 45 × 10 9 /l and the peripheral blood smear showed a leukoerythroblastic picture with a few circulating plasma cells. BM aspiration was a dry tap whereas the BM biopsy disclosed a mixture of diffuse and focal infiltrates of large plasma cells with anaplastic features and a high mitotic index. No monoclonal protein was detectable in the serum or urine by immunofixation, and the skeletal survey showed no osteolytic lesions.
Cyclosporine was discontinued, 3, 8 and he received a course of EDAP (etoposide-dexamethasone-cytarabinecisplatin) chemotherapy which was immediately followed by a single infusion of 2.9 × 10 8 nucleated donor leukocytes/kg containing 1.4% CD34 + and 37% CD3 + cells. The cells were collected on day 4 after giving 12 mg/kg G-CSF (filgrastim) to the donor from days 1 to 4. A 7-day period of myelosuppression ensued with subsequent gradual increase and normalisation of the counts. Bone marrow aspiration 18 days after donor cell infusion showed 6% plasmablasts, and a biopsy on day +30 showed a cellularity of 50% with normal hematopoiesis and Ͻ2% plasma cells. A few days later, three small (1.0-1.2 cm in diameter) subcutaneous nodules appeared on the head (n = 2) and on the left anterior chest wall (n = 1). The lesions were not attached to the skin and did not arise from the underlying bone.
On the basis of these findings, the good clinical condition of the patient, and a report of the successful use of interferon-␣ in acute myeloid leukemia with extramedullary recurrence, 10 interferon-␣ 2 MU was started every other day from day +36 onwards. The nodules enlarged over the next 5 weeks, and became hard and painful; the biggest reaching a maximum size of 7.5 × 4.5 × 1.5 cm. Following two unsuccessful attempts to aspirate material from the tumors, extramedullary plasmacytoma was histologically proven on day +70 (surgical excision). Bone marrow examination on the same day showed 2% plasma cells. Acute hepatic GVHD (+++) diagnosed clinically on the basis of jaundice and elevated liver enzymes (particularly alkaline phosphatase) developed on day +79. This was successfully treated with high-dose methyprednisolone. While arrangements for local radiotherapy of the plasmacytomas were underway, mild thrombocytopenia was noted on day +90 and systemic relapse was confirmed by BM aspiration (18% plasmablasts). The patient declined further treatment, and died 102 days after the donor leukocytes, transfusion independent and 37 months from his original diagnosis.
Discussion
Myeloma recurrence is a major cause of failure after allogeneic transplantation. 2 In spite of their proven chemoradiosensitivity, malignant plasma cells exhibit a remarkable ability to survive a variety of conditioning regimens, and therapeutic options in this setting are limited. Post-allograft myeloma can be successfully treated with immune manipulations including donor leukocyte infusions to evoke graftversus-myeloma. [3] [4] [5] [6] [7] This patient had disease which had been relatively refractory to chemotherapy prior to the transplant. It is therefore unlikely that the remission obtained following the post-allograft relapse was the result of the single course of salvage chemotherapy alone, and the abrupt withdrawal of cyclosporine and donor cells contributed to the response at least partially.
The prompt resolution of BM plasmacytosis and concurrent hematological improvement are in keeping with the observations of other groups. Tricot et al 4 demonstrated clearance of paraprotein and plasma cells in less than 1 month following administration of donor leukocytes in a patient who relapsed after a T cell-depleted matched unrelated donor transplant. Similarly, Munshi et al 11 from the same center reported that three out of four responding MM patients achieved complete remission between 4 and 6 weeks post infusion.
Unusual relapses have been seen after allogeneic transplantation for myeloma in the form of isolated osteolytic lesions 12 or subcutaneous tumors. 13 This is the first report of extramedullary myeloma relapse after cellular immunotherapy which had apparently succeeded in keeping the disease in the marrow under control. Extra-osseous plasma cell tumors are extremely rare at diagnosis and are more often encountered in terminal stages of myeloma in association with adjacent bone destruction. 14 Extramedullary relapse of leukemia has been described in patients whose marrows remained in remission: Singhal et al 15 described four occurrences of granulocytic sarcomas in three patients with acute myeloid leukemia, and one patient with Philadelphia chromosome-positive acute lymphoblastic leukemia who attained marrow remission but developed meningeal relapse on immunotherapy. 16 Tringali et al 17 described a patient who experienced an isolated testicular relapse of acute myeloid leukemia after achieving marrow remission with donor leukocytes. These cases and the emergence of plasmablastic plasmacytomas despite the continuing marrow remission in our case have an obscure pathogenesis, and may imply that the disappearance of malignant cells from the marrow may not be a definitive indicator of disease eradication.
While it is not impossible that skin may be an immunologically privileged site, allogeneic lymphocytes do reach the dermis after bone marrow transplantation, and successful regression of plasmacytic and leukemic skin infiltrates has been achieved with donor cell infusion. 12, 18 Limitation of the potency of graft-versus-tumour reactions which could be overcome by aggressive plasmablastic growth locally could explain the course of the disease in our patient.
Relapse of the underlying malignancy after successful control of immunotherapy-induced GVHD has been described before. 8, 10 It is possible that if our patient had not been started on immunosuppression immediately, the marrow relapse would not have occurred. It is also possible that the plasmacytomas would have shrunk with the onset of frank GVHD when they had continued to grow in the absence of GVHD.
The encouraging short-term efficacy of cell-mediated immunotherapy in myeloma may allow wider application and evaluation of this treatment modality in the future. More cases of unconventional disease recurrence are then likely to be seen due to subclinical seeding of surviving tumour cells into extramedullary tissues. Until more is known about this phenomenon, we speculate that ongoing active chronic GVHD may be the only protection against relapse, with more intense GVHD being required for protection against extramedullary relapse.
